| Year |
Citation |
Score |
| 2021 |
Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, et al. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. Plos One. 16: e0252048. PMID 34264955 DOI: 10.1371/journal.pone.0252048 |
0.317 |
|
| 2019 |
Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, Shen R, Pan L, Agarwal G, Ren Y, Roberts RD, O'Keefe BR, Kinghorn AD, Collins JM. Targeting protein translation by rocaglamide and didesmethylrocaglamide to treat MPNST and other sarcomas. Molecular Cancer Therapeutics. PMID 31848295 DOI: 10.1158/1535-7163.Mct-19-0809 |
0.397 |
|
| 2018 |
Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, et al. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. Plos One. 13: e0197350. PMID 29897904 DOI: 10.1371/Journal.Pone.0197350 |
0.577 |
|
| 2018 |
Beauchamp R, Erdin S, Angus S, Stuhlmiller T, Oblinger J, Jordan J, Haggarty SJ, R. Plotkin S, Chang L, L. Johnson G, F. Gusella J, Ramesh V. CSIG-42. HIGH THROUGHPUT KINOME AND TRANSCRIPTOME ANALYSES REVEAL NOVEL THERAPEUTIC TARGETS IN NF2-DEFICIENT MENINGIOMA Neuro-Oncology. 20: vi52-vi52. DOI: 10.1093/Neuonc/Noy148.208 |
0.314 |
|
| 2017 |
Fuse MA, Klingeman Plati S, Burns SS, Dinh CT, Bracho O, Yan D, Mittal R, Shen R, Soulakova JN, Copik AJ, Liu XZ, Telischi FF, Chang LS, Franco MC, Fernandez-Valle C. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Molecular Cancer Therapeutics. PMID 28775147 DOI: 10.1158/1535-7163.Mct-17-0417 |
0.433 |
|
| 2017 |
Oblinger JL, Burns SS, Huang J, Pan L, Ren Y, Shen R, Douglas Kinghorn A, Bradley Welling D, Chang LS. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Experimental Neurology. PMID 28610844 DOI: 10.1016/J.Expneurol.2017.06.015 |
0.406 |
|
| 2017 |
Petrilli AM, Garcia J, Bott M, Klingeman Plati S, Dinh CT, Bracho OR, Yan D, Zou B, Mittal R, Telischi FF, Liu XZ, Chang LS, Welling DB, Copik AJ, Fernández-Valle C. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. Oncotarget. PMID 28427224 DOI: 10.18632/Oncotarget.15912 |
0.447 |
|
| 2016 |
Burns SS, Chang LS. Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma. Methods in Molecular Biology (Clifton, N.J.). 1427: 59-72. PMID 27259921 DOI: 10.1007/978-1-4939-3615-1_4 |
0.386 |
|
| 2016 |
Oblinger JL, Burns SS, Akhmametyeva EM, Huang J, Pan L, Ren Y, Shen R, Miles-Markley B, Moberly AC, Kinghorn AD, Welling DB, Chang LS. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro-Oncology. PMID 26951381 DOI: 10.1093/Neuonc/Now032 |
0.586 |
|
| 2015 |
Chow HY, Dong B, Duron SG, Campbell DA, Ong CC, Hoeflich KP, Chang LS, Welling DB, Yang ZJ, Chernoff J. Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget. 6: 1981-94. PMID 25596744 DOI: 10.18632/Oncotarget.2810 |
0.655 |
|
| 2014 |
Petrilli A, Copik A, Posadas M, Chang LS, Welling DB, Giovannini M, Fernández-Valle C. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene. 33: 3571-82. PMID 23934191 DOI: 10.1038/onc.2013.320 |
0.615 |
|
| 2013 |
Spear SA, Burns SS, Oblinger JL, Ren Y, Pan L, Kinghorn AD, Welling DB, Chang LS. Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 34: 1519-27. PMID 23928514 DOI: 10.1097/Mao.0B013E3182956169 |
0.561 |
|
| 2013 |
Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, Chen CS, Jacob A, Welling DB, Chang LS. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Research. 73: 792-803. PMID 23151902 DOI: 10.1158/0008-5472.Can-12-1888 |
0.6 |
|
| 2012 |
Bush ML, Burns SS, Oblinger J, Davletova S, Chang LS, Welling DB, Jacob A. Treatment of vestibular schwannoma cells with ErbB inhibitors. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 33: 244-57. PMID 22222570 DOI: 10.1097/Mao.0B013E31823E287F |
0.541 |
|
| 2012 |
Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, Kulp S, La Perle KM, Chen CS, Chang LS, Welling DB. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope. 122: 174-89. PMID 22109824 DOI: 10.1002/Lary.22392 |
0.598 |
|
| 2011 |
Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Yates CW, Chaudhury AR, Kulp S, Chen CS, Chang LS, Welling DB, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology. 13: 983-99. PMID 21778190 DOI: 10.1093/Neuonc/Nor072 |
0.604 |
|
| 2010 |
Chai G, Liu N, Ma J, Li H, Oblinger JL, Prahalad AK, Gong M, Chang LS, Wallace M, Muir D, Guha A, Phipps RJ, Hock JM, Yu X. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Science. 101: 1997-2004. PMID 20550523 DOI: 10.1111/J.1349-7006.2010.01616.X |
0.323 |
|
| 2009 |
Lee TX, Packer MD, Huang J, Akhmametyeva EM, Kulp SK, Chen CS, Giovannini M, Jacob A, Welling DB, Chang LS. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. European Journal of Cancer (Oxford, England : 1990). 45: 1709-20. PMID 19359162 DOI: 10.1016/J.Ejca.2009.03.013 |
0.565 |
|
| 2009 |
Chang LS, Welling DB. Molecular biology of vestibular schwannomas. Methods in Molecular Biology (Clifton, N.J.). 493: 163-77. PMID 18839347 DOI: 10.1007/978-1-59745-523-7_10 |
0.62 |
|
| 2009 |
Bush ML, Oblinger J, Kulp S, Chen C, Jacob A, Welling III DB, Chang L. Novel inhibitors of vestibular schwannomas and meningiomas Otolaryngology - Head and Neck Surgery. 141: P87-P88. DOI: 10.1016/J.Otohns.2009.06.268 |
0.301 |
|
| 2009 |
Oblinger J, Bush ML, Wheeler J, Chen C, Jacob A, Welling DB, Chang L. HDAC-42 as a potential radiosensitizer for human schwannomas Otolaryngology - Head and Neck Surgery. 141: P81-P81. DOI: 10.1016/J.Otohns.2009.06.248 |
0.539 |
|
| 2008 |
Dorogova NV, Akhmametyeva EM, Kopyl SA, Gubanova NV, Yudina OS, Omelyanchuk LV, Chang LS. The role of Drosophila Merlin in spermatogenesis. Bmc Cell Biology. 9: 1. PMID 18186933 DOI: 10.1186/1471-2121-9-1 |
0.332 |
|
| 2007 |
Welling DB, Packer MD, Chang LS. Molecular studies of vestibular schwannomas: a review. Current Opinion in Otolaryngology & Head and Neck Surgery. 15: 341-6. PMID 17823551 DOI: 10.1097/Moo.0B013E3282B97310 |
0.536 |
|
| 2006 |
Chang LS, Jacob A, Abraham J, Lorenz M, Rock J, Akhmametyeva EM, Mihai G, Schmalbrock P, Chaudhury AR, Lopez R, Yamate J, John MR, Wickert H, Neff BA, Dodson E, et al. Growth of benign and malignant schwannoma xenografts in severe combined immunodeficiency mice. The Laryngoscope. 116: 2018-26. PMID 17075413 DOI: 10.1097/01.Mlg.0000240185.14224.7D |
0.511 |
|
| 2006 |
Akhmametyeva EM, Mihaylova MM, Luo H, Kharzai S, Welling DB, Chang LS. Regulation of the neurofibromatosis 2 gene promoter expression during embryonic development. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 235: 2771-85. PMID 16894610 DOI: 10.1002/Dvdy.20883 |
0.602 |
|
| 2006 |
Neff BA, Oberstien E, Lorenz M, Chaudhury AR, Welling DB, Chang LS. Cyclin D(1) and D(3) expression in vestibular schwannomas. The Laryngoscope. 116: 423-6. PMID 16540902 DOI: 10.1097/01.Mlg.0000195076.05466.6C |
0.556 |
|
| 2006 |
Neff BA, Welling DB, Akhmametyeva E, Chang LS. The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 27: 197-208. PMID 16436990 DOI: 10.1097/01.Mao.0000180484.24242.54 |
0.536 |
|
| 2005 |
Golovnina K, Blinov A, Akhmametyeva EM, Omelyanchuk LV, Chang LS. Evolution and origin of merlin, the product of the Neurofibromatosis type 2 (NF2) tumor-suppressor gene. Bmc Evolutionary Biology. 5: 69. PMID 16324214 DOI: 10.1186/1471-2148-5-69 |
0.388 |
|
| 2005 |
Popov B, Chang LS, Serikov V. Cell cycle-related transformation of the E2F4-p130 repressor complex. Biochemical and Biophysical Research Communications. 336: 762-9. PMID 16153605 DOI: 10.1016/J.Bbrc.2005.08.163 |
0.307 |
|
| 2003 |
Xu Z, Huang S, Chang LS, Agulnick AD, Brandt SJ. Identification of a TAL1 target gene reveals a positive role for the LIM domain-binding protein Ldb1 in erythroid gene expression and differentiation. Molecular and Cellular Biology. 23: 7585-99. PMID 14560005 DOI: 10.1128/Mcb.23.21.7585-7599.2003 |
0.347 |
|
| 2003 |
Lo WD, Akhmametyeva EM, Zhu L, Friesen PD, Chang LS. Induction of apoptosis by the p53-related p73 and partial inhibition by the baculovirus-encoded p35 in neuronal cells. Brain Research. Molecular Brain Research. 113: 1-12. PMID 12750001 DOI: 10.1016/S0169-328X(03)00052-4 |
0.308 |
|
| 2002 |
Lasak JM, Welling DB, Akhmametyeva EM, Salloum M, Chang LS. Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas. The Laryngoscope. 112: 1555-61. PMID 12352662 DOI: 10.1097/00005537-200209000-00004 |
0.58 |
|
| 2002 |
Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B, Chang LS. cDNA microarray analysis of vestibular schwannomas. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 23: 736-48. PMID 12218628 DOI: 10.1097/00129492-200209000-00022 |
0.604 |
|
| 2002 |
Chang LS, Akhmametyeva EM, Wu Y, Zhu L, Welling DB. Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts. Genomics. 79: 63-76. PMID 11827459 DOI: 10.1006/Geno.2001.6672 |
0.59 |
|
| 2000 |
Welling DB, Akhmametyeva EM, Daniels RL, Lasak JM, Zhu L, Miles-Markley BA, Chang LS. Analysis of the human neurofibromatosis type 2 gene promoter and its expression. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 123: 413-8. PMID 11020177 DOI: 10.1067/Mhn.2000.107683 |
0.61 |
|
| 2000 |
Reshetnikova G, Barkan R, Popov B, Nikolsky N, Chang LS. Disruption of the actin cytoskeleton leads to inhibition of mitogen-induced cyclin E expression, Cdk2 phosphorylation, and nuclear accumulation of the retinoblastoma protein-related p107 protein. Experimental Cell Research. 259: 35-53. PMID 10942577 DOI: 10.1006/Excr.2000.4966 |
0.367 |
|
| 2000 |
Welling DB, Chang LS. All in a name: schwannomin versus merlin. The American Journal of Otology. 21: 289. PMID 10733201 |
0.45 |
|
| 1999 |
Karacay B, Chang LS. Induction of erythrocyte protein 4.2 gene expression during differentiation of murine erythroleukemia cells Genomics. 59: 6-17. PMID 10395794 DOI: 10.1006/Geno.1999.5846 |
0.367 |
|
| 1998 |
Zhu L, Kahwash SB, Chang L. Developmental expression of mouse erythrocyte protein 4.2 mRNA: evidence for specific expression in erythroid cells Blood. 91: 695-705. DOI: 10.1182/Blood.V91.2.695.695_695_705 |
0.326 |
|
| 1997 |
Lee Y, Chen Y, Chang LS, Johnson LF. Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. Experimental Cell Research. 234: 270-6. PMID 9260894 DOI: 10.1006/Excr.1997.3605 |
0.38 |
|
| 1997 |
Zhao L, Chang LS. The human POLD1 gene: Identification of an upstream activator sequence, activation by Sp1 and Sp3, and cell cycle regulation Journal of Biological Chemistry. 272: 4869-4882. PMID 9030545 DOI: 10.1074/Jbc.272.8.4869 |
0.331 |
|
| 1996 |
Xie E, Zhu L, Zhao L, Chang L. The Human Serotonin 5-HT2CReceptor: Complete cDNA, Genomic Structure, and Alternatively Spliced Variant ☆ Genomics. 35: 551-561. PMID 8812491 DOI: 10.1006/Geno.1996.0397 |
0.327 |
|
| 1990 |
Chang LS, Shenk T. The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adeno-associated virus promoters Journal of Virology. 64: 2103-2109. PMID 2157873 DOI: 10.1128/Jvi.64.5.2103-2109.1990 |
0.325 |
|
| 1990 |
Yu UA, Suen TC, Yan DH, Chang LS, Hung MC. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products Proceedings of the National Academy of Sciences of the United States of America. 87: 4499-4503. PMID 1972274 DOI: 10.1073/Pnas.87.12.4499 |
0.32 |
|
| Show low-probability matches. |